USA - NASDAQ:EPIX - CA29668H7085 - Common Stock
ChartMill assigns a Buy % Consensus number of 46% to EPIX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating | 
|---|---|---|---|
| 2024-11-04 | Oppenheimer | Downgrade | Outperform -> Perform | 
| 2024-11-04 | Piper Sandler | Downgrade | Overweight -> Neutral | 
| 2024-11-01 | Jones Trading | Downgrade | Buy -> Hold | 
| 2024-05-16 | Oppenheimer | Maintains | Outperform -> Outperform | 
| 2023-12-13 | Oppenheimer | Reiterate | Outperform -> Outperform | 
| 2023-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform | 
| 2022-05-12 | Piper Sandler | Maintains | Overweight | 
| 2021-08-17 | Oppenheimer | Maintains | Outperform | 
| 2021-03-04 | Piper Sandler | Initiate | Overweight | 
| 2021-02-25 | HC Wainwright & Co. | Maintains | Buy | 
| 2021-02-11 | HC Wainwright & Co. | Maintains | Buy | 
7 analysts have analysed EPIX and the average price target is 1.73 USD. This implies a price increase of 761.83% is expected in the next year compared to the current price of 0.2012.
The consensus rating for ESSA Pharma Inc (EPIX) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.